NeuroOne (NMTC) Q2 2026 earnings review
Strong YoY Growth Masked by Sequential Deceleration and Cash Burn Concerns
NeuroOne delivered $2.4M in Q2 product revenue, marking a solid 72% YoY increase driven by Zimmer Biomet's distribution of the OneRF Brain Ablation System. However, this represents a sequential deceleration from Q1's $2.9M. While the company maintained flat operating expenses and narrowed its net loss to $2.1M, the balance sheet is flashing warning signs. Cash plummeted to $2.8M, forcing reliance on $2.4M in tied-up accounts receivable to fund near-term operations. A 1-for-6 reverse split cured Nasdaq compliance, but management must now urgently execute strategic partnerships for its trigeminal and pain pipelines to avoid dilutive financing.
🐂 Bull Case
The OneRF Trigeminal Nerve Ablation System has now treated 16 patients with a 100% pain-free success rate. Its single-placement design offers a distinct clinical advantage over legacy multi-placement probes.
Total operating expenses actually declined slightly YoY to $3.39M despite product revenue surging 72%. Gross margins remain stable at ~54%, showing the business can scale without linear cost increases.
🐻 Bear Case
Cash stands at just $2.8M against a $2.1M quarterly net loss. Even with $2.4M in accounts receivable expected to convert in Q3, the company operates with a razor-thin cash cushion.
Sequential revenue dropped 17% from Q1 to Q2. With a single customer (Zimmer Biomet) accounting for 99.4% of product revenue, NeuroOne is entirely at the mercy of one partner's ordering cadence.
⚖️ Verdict: ⚪
Neutral. The technology clearly works, and the core epilepsy business is expanding YoY. However, the sequentially weaker quarter, an uncomfortably low cash balance, and reliance on unfinalized partnership deals inject significant near-term execution risk.
Key Themes
Cash Position and Accounts Receivable Spike
A major red flag is liquidity. Cash dropped from $6.6M at FY25 year-end to just $2.8M at the end of Q2 26. Simultaneously, Accounts Receivable spiked to $2.4M (from $1.26M at FY25 year-end). Management explicitly noted that converting this A/R in Q3 is critical to funding operations. Without immediate collections or a non-dilutive partnership upfront payment, the company risks further dilutive equity raises following its recent 1-for-6 reverse stock split.
Sequential Deceleration Highlights Single-Partner Risk
Product revenue is decelerating sequentially, dropping from $2.89M in 26Q1 to $2.39M in 26Q2. The 10-Q filing reveals one customer (Zimmer Biomet) accounted for 99.4% of Q2 revenue. This intense concentration means NeuroOne has virtually zero control over its quarterly revenue trajectory, which will fluctuate violently based on Zimmer's inventory stocking and destocking cycles.
Trigeminal Ablation Proving Clinical Superiority
The trigeminal neuralgia program is emerging as a powerful growth driver. To date, 16 cases have been completed with a 100% pain-free outcome rate. The technology's specific innovation—multiple contacts on a single probe—eliminates the need for repeated probe placements, significantly improving patient comfort and shortening procedure times. This positions the device to disrupt the $780M trigeminal neuralgia market.
Drug Delivery Advancing Ahead of Schedule
The sEEG-based drug delivery program remains a critical future catalyst. Management confirmed that final device builds are in progress and the system remains on track for investigational/animal use availability in H2 2026. The new collaboration with the University of Minnesota to test next-generation epilepsy therapies validates external demand for this platform.
International Expansion Nearing Regulatory Threshold
NeuroOne completed its Stage 2 ISO 13485 audit for its Minnesota facility. Securing this certification by late 2026 is the mandatory gateway to commercializing the product suite in outside-the-U.S. (OUS) geographies that recognize FDA clearance, opening a massive untapped market.
Other KPIs
Stable. Gross margin remained steady, down slightly from 55.6% a year ago and 54.2% in 26Q1. The slight compression was attributed to a change in sales mix and higher component costs. The ability to hold margins above 50% while scaling early commercial volumes is a positive indicator for long-term profitability.
Stable. Total Opex fell slightly from $3.45M in 25Q2. R&D was flat at $1.47M, and SG&A was tightly controlled at $1.92M. This disciplined cost control is vital given the current cash constraints.
Guidance
Stable. Management reaffirmed their full-year guidance in the Q&A. Achieving $10.5M implies at least 17% YoY growth over FY25's $9.1M. With $5.28M generated in H1, the company needs to average ~$2.6M per quarter in H2, which implies stable to slightly accelerating sequential performance compared to Q2's $2.39M.
Key Questions
Trigeminal Partnership Timeline
You are currently undertaking a limited market release for the Trigeminal Nerve Ablation System while evaluating distribution options. Given current cash constraints, what is the realistic timeline for securing a strategic partner, and is an upfront payment part of those negotiations?
Accounts Receivable Conversion
Accounts Receivable spiked to $2.4M, nearly matching your current cash balance. Are there any extended payment terms with Zimmer Biomet contributing to this, and how certain are you that this will fully convert to cash in Q3?
Zimmer Biomet End-User Metrics
While Zimmer handles sales and marketing, product revenue dropped sequentially this quarter. Do you have visibility into whether this drop was due to Zimmer destocking inventory, or a slowdown in actual hospital procedure volumes?